Precigen, Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending September 29, 2021 was 86.55% (a 45.34% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -39.48%
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 88.88% (a -18.25% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 108.72% (a 30.7% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 83.18% (a 33.88% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending September 29, 2021 was 85.88% (a -2.14% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by -0.77% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
85.88% 87.76% 88.42% 86.55%
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Precigen, Inc.

Most recent Selling, General and Administrative Expense of Revenueof PGEN including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Precigen, Inc.

Precigen, Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 86.55% 59.55% 76.3%
2020 143.0% 94.56% 58.73% 72.01% 88.88%
2019 153.79% 121.25% 58.62% 137.48% 108.72%
2018 36.37% 119.29% 76.04% 100.18% 83.18%
2017 26.7% 85.36% 71.36% 65.38% 62.13%
2016 76.87% 69.03% 57.64% 98.72% 72.32%
2015 83.71% 43.13% 52.73% 81.62% 62.82%
2014 63.61% 70.07% 130.5% 173.61% 88.49%
2013 172.15% 122.59% 111.12% 166.8% 141.49%
2012 172.51% 232.32% 180.75%
2011 228.38%

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.